PMDA vs FDA: Medical Device Regulation in Japan and the United States

Japan and the United States are both mature medical device markets, but their regulatory systems are structured differently. The U.S. Food and Drug Administration (FDA) operates as a centralized national authority for medical devices through CDRH. Japan separates policy authority and technical review across the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

This guide compares PMDA and FDA medical device regulation for teams planning market access, competitor monitoring, or recurring regulatory intelligence workflows across Japan and the United States.

Regulatory bodies

Japan: MHLW and PMDA

In Japan, MHLW is the government ministry responsible for health policy and legal authority over pharmaceuticals and medical devices. PMDA conducts scientific review, safety work, and related technical functions under Japan's Pharmaceuticals and Medical Devices Act framework.

For manufacturers, this means Japan monitoring should not be limited to a single agency webpage. PMDA review information, MHLW policy updates, safety communications, and product-level signals can all matter to Japan market access strategy.

United States: FDA and CDRH

In the United States, medical devices are regulated by FDA, primarily through the Center for Devices and Radiological Health (CDRH). FDA handles device classification, premarket review, registration and listing, safety communications, recalls, adverse event programs, and post-market enforcement.

The practical difference is that FDA is a more centralized operational point for U.S. device regulation, while Japan monitoring requires teams to watch PMDA and MHLW together.

Classification and review logic

Both Japan and the United States use risk-based classification, but teams should avoid assuming that a device's U.S. class maps neatly to its Japan category.

FDA classification

FDA generally classifies devices into Class I, Class II, and Class III. Class I devices are usually lower risk and often exempt from premarket notification. Many Class II devices require a 510(k) premarket notification. Higher-risk Class III devices typically require Premarket Approval (PMA), unless another pathway applies.

Japan classification

Japan uses a risk-based classification structure that is commonly described across four classes, with regulatory handling tied to risk, certification, approval, and the role of registered certification bodies for some device types. Novel or higher-risk devices usually require more direct PMDA/MHLW review than lower-risk categories.

The key planning point is simple: classify independently for each market. A device cleared through 510(k) in the United States may still require a different evidence package or procedural route in Japan.

Premarket pathways

FDA pathways

The main U.S. device pathways include:

• 510(k) premarket notification for many moderate-risk devices that can show substantial equivalence to a legally marketed predicate.
• De Novo classification for novel low-to-moderate risk devices without a suitable predicate.
• Premarket Approval (PMA) for many high-risk Class III devices, usually supported by more extensive clinical evidence.

This creates a pathway-driven system. Classification matters, but the practical submission strategy often turns on whether a predicate exists, whether the device is novel, and whether clinical evidence is needed.

Japan pathways

Japan pathways depend on the device type, risk class, certification standards, and whether the product can be reviewed through certification or requires approval. PMDA's role becomes especially important where technical review, novelty, safety questions, or higher-risk product categories are involved.

For foreign manufacturers, Japan planning also commonly involves local representation, Japanese-language documentation, Japan-specific labeling, and careful alignment with local requirements before submission.

Comparison table

Area	Japan PMDA / MHLW	U.S. FDA
Main authority structure	MHLW policy authority with PMDA technical review and safety functions	FDA/CDRH centralized device authority
Common classification model	Risk-based, commonly described across four classes	Class I, II, III
Moderate-risk route	Certification or approval route depends on device and standards	Usually 510(k), unless exempt or De Novo applies
Novel low-to-moderate risk route	Often requires Japan-specific route analysis	De Novo request can create a new classification
High-risk route	Approval with deeper technical review	PMA with valid scientific evidence
Language and local requirements	Japanese documentation and local market access setup are central	English submissions; foreign firms use U.S. Agent where applicable
Post-market focus	Safety information, vigilance, MHLW/PMDA communications, local obligations	MDR reporting, recalls, corrections/removals, inspections, post-market surveillance
Monitoring challenge	PMDA and MHLW signals should be watched together	FDA device databases and CDRH communications are central monitoring points

Evidence and clinical data considerations

Evidence planning is where PMDA vs FDA differences become operationally expensive.

In the United States, a 510(k) often relies on performance testing and substantial equivalence, while PMA typically requires stronger clinical evidence. De Novo submissions sit between these cases, depending on device risk and novelty.

For Japan, manufacturers should assess whether existing global evidence will satisfy local expectations and whether additional Japan-specific evidence, bridging rationale, or localized documentation will be needed. The answer can depend on device type, novelty, patient population, standards, and PMDA/MHLW expectations.

The practical recommendation is to evaluate Japan evidence needs before locking a global clinical and regulatory plan. Treating PMDA review as a late translation step creates avoidable delays.

Post-market monitoring

Post-market monitoring also differs by operating model.

For FDA, teams commonly monitor recalls, medical device reports, safety communications, warning letters, product registrations, 510(k) clearances, De Novo decisions, and PMA approvals.

For Japan, teams should watch PMDA safety information, MHLW policy updates, product approval information, and local market access developments. PMDA and MHLW signals can affect quality, regulatory, clinical, and commercial planning.

What teams should monitor weekly

For cross-market regulatory intelligence, a useful weekly review should cover:

1. FDA 510(k), De Novo, PMA, recall, warning letter, and safety activity.
2. PMDA and MHLW review, safety, and policy signals.
3. Product category changes that affect both Japan and U.S. launch strategy.
4. Competitor activity in device categories where Japan and the United States move at different speeds.
5. New source activity that may affect post-market surveillance, labeling, clinical evidence, or registration planning.

Strategic takeaways

• Do not assume FDA clearance makes Japan approval straightforward.
• Classify independently for Japan and the United States.
• Watch PMDA and MHLW together, not PMDA alone.
• Compare Japan signals with FDA activity to identify category momentum and competitor movement.
• Build Japan evidence and documentation assumptions early, especially for novel or higher-risk devices.

Official source context

• PMDA review services for medical devices
• PMDA approved medical device information
• MHLW pharmaceuticals and medical devices policy
• FDA medical devices overview
• FDA 510(k) clearances
• FDA De Novo classification requests
• FDA Premarket Approval

---

MedFlux monitors Japan and U.S. medical device signals side by side, including PMDA, MHLW, FDA clearances, recalls, safety notices, and weekly country reports. Use the Japan weekly reports to track whether PMDA-related activity is changing in your product category.